At the 2022 annual meeting of the American Society of Clinical Oncology (ASCO 22), Shanghai-based cancer company I-Mab is presenting new Phase I data for uliled 30 May 2022
A new kind of treatment which raises the prospect of an off-the-shelf approach to CAR T-cell therapy has scored an early-stage win, lifting shares in developer 27 May 2022
Budget medicine specialist EQRx (Nasdaq: EQRX), a company focused on delivering innovative medicines at significantly lower prices, will present new data for it 27 May 2022
US biotech major Amgen has promised new data from across its oncology innovative medicines and biosimilars portfolio and pipeline at the American Society of Cli 27 May 2022
The world’s leading cancer conference kicks off in Chicago on Friday 3 June, and for many industry participants, it will be the first time they have attended a 25 May 2022
US pharma giant Merck & Co has announced the final results from the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab) plus best supportive care 19 January 2022
The Franco-American pairing of Ipsen and Exelixis have announced detailed results from the Phase III COSMIC-311 pivotal trial of Cabometyx (cabozantinib) in pre 9 June 2021
New research led by the Roswell Park Comprehensive Cancer Center in Buffalo, USA, shows that treatment with checkpoint blockers has led to a significant improve 8 June 2021
Chinese biopharma BeiGene has announced data from two pivotal trials of its anti-PD-1 antibody tislelizumab at the 2021 American Society of Clinical Oncology An 7 June 2021
At the annual meeting of the American Society of Clinical Oncology, Gilead Sciences subsidiary Kite has presented encouraging data from a primary analysis of th 7 June 2021
AstraZeneca and Merck & Co’s Lynparza (olaparib) has become the first drug targeting BRCA mutations to show clinical benefit in the adjuvant setting. 4 June 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.